Cargando…

The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.

Seven patients with small volume ovarian carcinoma, remaining after conventional therapy with surgery and a platinum containing chemotherapy regimen, were treated with intraperitoneal monoclonal antibody guided radiotherapy. 100 mCi131I conjugated to 10 mg of monoclonal antibody were injected i.p. i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, B., Mather, S., Shepherd, J., Crowther, M., Hawkins, L., Britton, K., Slevin, M. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246825/
https://www.ncbi.nlm.nih.gov/pubmed/3219277
_version_ 1782150849781301248
author Ward, B.
Mather, S.
Shepherd, J.
Crowther, M.
Hawkins, L.
Britton, K.
Slevin, M. L.
author_facet Ward, B.
Mather, S.
Shepherd, J.
Crowther, M.
Hawkins, L.
Britton, K.
Slevin, M. L.
author_sort Ward, B.
collection PubMed
description Seven patients with small volume ovarian carcinoma, remaining after conventional therapy with surgery and a platinum containing chemotherapy regimen, were treated with intraperitoneal monoclonal antibody guided radiotherapy. 100 mCi131I conjugated to 10 mg of monoclonal antibody were injected i.p. in 2,000 ml peritoneal dialysis fluid. Patients were evaluated 3 months later; 3 had clinical progressive disease while third look laparotomy demonstrated progressive disease in 3 of the remaining 4 patients. The seventh patient did not have a third look laparotomy and is currently inevaluable for response. Five patients with recurrent malignant ascites not controlled by diuretics or repeated paracentesis were similarly treated with 75-170 mCi131I conjugated to 10 mg monoclonal antibody. In three patients the ascites was controlled for a mean of 4 months. One patient died too early to assess the control of his ascites but tumour cells disappeared from the ascitic fluid after therapy. In the patient whose ascites were not controlled, a subpopulation of antigen-negative tumour cells was demonstrated. This study was unable to demonstrate a therapeutic benefit for i.p. injected monoclonal antibody guided radiotherapy for solid intraperitoneal tumour but suggests that it may be capable of controlling the accumulation of antigen positive malignant ascites. IMAGES:
format Text
id pubmed-2246825
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22468252009-09-10 The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. Ward, B. Mather, S. Shepherd, J. Crowther, M. Hawkins, L. Britton, K. Slevin, M. L. Br J Cancer Research Article Seven patients with small volume ovarian carcinoma, remaining after conventional therapy with surgery and a platinum containing chemotherapy regimen, were treated with intraperitoneal monoclonal antibody guided radiotherapy. 100 mCi131I conjugated to 10 mg of monoclonal antibody were injected i.p. in 2,000 ml peritoneal dialysis fluid. Patients were evaluated 3 months later; 3 had clinical progressive disease while third look laparotomy demonstrated progressive disease in 3 of the remaining 4 patients. The seventh patient did not have a third look laparotomy and is currently inevaluable for response. Five patients with recurrent malignant ascites not controlled by diuretics or repeated paracentesis were similarly treated with 75-170 mCi131I conjugated to 10 mg monoclonal antibody. In three patients the ascites was controlled for a mean of 4 months. One patient died too early to assess the control of his ascites but tumour cells disappeared from the ascitic fluid after therapy. In the patient whose ascites were not controlled, a subpopulation of antigen-negative tumour cells was demonstrated. This study was unable to demonstrate a therapeutic benefit for i.p. injected monoclonal antibody guided radiotherapy for solid intraperitoneal tumour but suggests that it may be capable of controlling the accumulation of antigen positive malignant ascites. IMAGES: Nature Publishing Group 1988-11 /pmc/articles/PMC2246825/ /pubmed/3219277 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ward, B.
Mather, S.
Shepherd, J.
Crowther, M.
Hawkins, L.
Britton, K.
Slevin, M. L.
The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title_full The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title_fullStr The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title_full_unstemmed The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title_short The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.
title_sort treatment of intraperitoneal malignant disease with monoclonal antibody guided 131i radiotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246825/
https://www.ncbi.nlm.nih.gov/pubmed/3219277
work_keys_str_mv AT wardb thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT mathers thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT shepherdj thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT crowtherm thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT hawkinsl thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT brittonk thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT slevinml thetreatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT wardb treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT mathers treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT shepherdj treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT crowtherm treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT hawkinsl treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT brittonk treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy
AT slevinml treatmentofintraperitonealmalignantdiseasewithmonoclonalantibodyguided131iradiotherapy